Tirzepatide vs Retatrutide.
Tirzepatide is an FDA-approved dual agonist (GIP and GLP-1). Retatrutide is an investigational triple agonist from the same company that adds a third target, glucagon. Retatrutide has posted larger average weight loss in its Phase 3 trials, but no trial has compared the two directly, and Retatrutide is not approved.
| Tirzepatide | Retatrutide | |
|---|---|---|
| Online nickname | "GLP-2T" | "GLP-3R" |
| How it works | Dual GIP and GLP-1 receptor agonist | Triple GIP, GLP-1 and glucagon receptor agonist |
| Maker | Eli Lilly | Eli Lilly |
| US status | FDA-approved (Mounjaro, Zepbound) | Investigational, clinical trials only |
| Key obesity trial result | SURMOUNT-5: 20.2% average at 72 weeks (10 or 15 mg) | TRIUMPH-1: up to 25.0% average at 80 weeks (12 mg) |
| How it is taken | Weekly injection | Weekly injection in trials |
Why the numbers cannot be compared directly
The trials enrolled different people, ran for different lengths of time and used different doses. A cross-trial comparison can suggest a difference but cannot prove one; only a head-to-head trial can, and none has been reported as of September 2026.
Where Retatrutide stands
Eli Lilly reported TRIUMPH-1 in May 2026: at 80 weeks average weight loss was 17.6%, 23.7% and 25.0% on 4, 9 and 12 mg, against 3.9% on placebo. TRIUMPH-2 (with type 2 diabetes) and TRIUMPH-3 (with cardiovascular disease) followed in July 2026 at up to 20.8% and 22.6%. Lilly has said it plans to file with the FDA in early 2027. Until approval, it is legally available only inside clinical trials; products sold online as "Retatrutide" or "GLP-3R" are unapproved and unregulated.
Tracking either one
For Tirzepatide: the injection day, each dose step, site rotation and supply. For a Retatrutide trial: study visit dates, your assigned dose, and weight and activity to bring to the study team.
- ACC: SURMOUNT-5, Tirzepatide vs Semaglutide (NEJM, 2025)
- HCPLive: Retatrutide TRIUMPH-1 Phase 3 results (May 2026)
- HCPLive: Retatrutide TRIUMPH-2 and TRIUMPH-3 results (July 2026)
- FDA: unapproved GLP-1 drugs used for weight loss
Common questions.
Is Retatrutide stronger than Tirzepatide?
Retatrutide has shown larger average weight loss in its own trials (up to 25.0% at 80 weeks in TRIUMPH-1) than Tirzepatide in its trials (20.2% at 72 weeks in SURMOUNT-5), but no head-to-head trial exists, so a direct claim cannot be made.
Is Retatrutide available?
Not outside clinical trials. As of September 2026 it is investigational and not approved anywhere.
When will Retatrutide be approved?
Eli Lilly has said it plans to submit it to the FDA in early 2027. Approval timing after that is up to the FDA.
What do "GLP-2T" and "GLP-3R" mean?
They are online nicknames for Tirzepatide and Retatrutide, counting the hormone receptors each one targets (two and three). They are not official names, and neither drug is a GLP-2 or GLP-3 medicine.
Can PRTCL track a clinical-trial protocol?
Yes. Log the weekly dose, injection day and site, and keep weight and activity from Health Connect alongside it.
Track it in one system.
PRTCL runs peptides, supplements, nutrition and training together, with reminders at the times you set, reconstitution math, site rotation and inventory that counts itself down. Launching on Android and iPhone the same day. Join the waitlist and enter the draw for one of 57 lifetime Premium subscriptions.